Stelis starts next phase of investment into its biologics manufacturing facility
This phase sees the CDMO start work on installing two 2,000-L single-use bioreactor trains in its mammalian cGMP facility.
Contract development and manufacturing organization (CDMO), Stelis BioSource, a division of Stelis Biopharma, has started the next phase of its continued investment program after having already invested more than $100 million into its facilities in Bangalore, India.
The latest phase will see the company, which offers end-to-end development and manufacturing services for biologics and biosimilars companies, start work on installing two 2,000-L single-use bioreactor trains in its mammalian cGMP facility.
The bioreactor trains will be added to the company’s 200,000 sq ft state-of-the-art manufacturing facility which became fully operational earlier this year. The new manufacturing facility, which caters for drug product and drug substance manufacture, allows Stelis BioSource to offer fully integrated services from early phase development through to commercial manufacture and fill finish.
In addition to the drug substance and drug product capabilities, which cover process scale-up and cGMP manufacturing to commercial scales, the facility offers the latest analytical methodologies and equipment and operates under Stelis’ fully compliant quality management system.
Dr Roger Lias, CEO at Stelis Biopharma said: “Our CDMO facility in Bangalore is already fully operational working on both new and existing customer projects. The investment has been driven by both strong market demand and multiple opportunities to develop an offering for the delivery of affordable outsourced capabilities for biologics".
The company, which is dedicated to driving down the cost of biologics, also has plans to develop the site further. The company continues to evaluate further investments into both capabilities and capacity to meet customer demand, including for those driven by the current Covid-19 pandemic.
Stay at the cutting edge at CPHI Barcelona
All over the industry, companies are upscaling, innovating and progressing. If you want to stay up to date on the latest trends and developments, join us at CPHI Barcelona. Meet representatives from over 1800 businesses including new ventures in our Start-Up Market.
Your CPHI Barcelona pass gives you access to all conference sessions, including the Quality Management track, as well as the chance to connect in-person with the global pharma supply chain from 24-26 October, at Fira Barcelona Gran Via. Browse the agenda and secure your pass today!
Learn more
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...